본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

초록보기

Background The high heterogeneity of basal-like breast cancer (BLBC) impedes early diagnosis and accurate prognosis. Beta-alanine, a non-essential amino acid involved in various metabolic pathways, accumulates in BLBC cells and may exacerbate tumor progression.

Objective This study aimed to develop a prognostic model based on beta-alanine metabolism genes and investigate the clinical significance and therapeutic potential of EHHADH in BLBC.

Methods We applied Least Absolute Shrinkage and Selection Operator regression to 22 beta-alanine metabolism genes to construct a prognostic model using transcriptomic data. Subsequent analyses included overall survival, mutation landscape, functional enrichment, drug sensitivity, and in vitro validation of EHHADH function. Structure-based virtual screening was conducted to identify potential EHHADH inhibitors.

Results A beta-alanine metabolism-related prognostic signature was successfully developed. EHHADH was identified as a risk gene negatively associated with survival. High EHHADH expression correlated with increased sensitivity to chemotherapeutic agents, including docetaxel, doxorubicin, gemcitabine, paclitaxel, tamoxifen, and vinorelbine. Knockdown of EHHADH reduced BLBC cell proliferation and migration. Virtual screening revealed several candidate small molecules targeting EHHADH.

Conclusion This study establishes a prognostic model based on beta-alanine metabolism in BLBC and identifies EHHADH as a potential biomarker and drug target, providing insights for precision therapy in metabolically reprogrammed breast cancer.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers Seo-Yeong Yoon, Gi-Eun Yang, Jong-Kil Nam, Hyeok-Jun Goh, Tae-Nam Kim, Sun-Hee Leem p. 1239-1251
(A) prognostic model for basal-like breast cancer based on beta-alanine metabolism genes : EHHADH as a potential biomarker and target for drug screening Xianjie Cheng, Birong Liu, Hong Lou, Fei Guo, Qiangsheng Xiao p. 1253-1266
Deep learning-driven whole-slide image analysis predicts chemo-resistance and motility subtypes in muscle-invasive bladder cancer Il-San Jeong, Jee-Woo Seo, Seung-Jin Park, Seon-Young Kim, Seon-Kyu Kim, Seung-Woo Baek p. 1267-1276
Association of MSH2, MSH6, and MLH1 polymorphisms with susceptibility and survival in lung cancer patients Jing Cheng, Chao Zuo, Dongli Yang, Yi Liu, Yu Wang, Yongchao Qiao p. 1277-1291
Epigenetic regulation of cereblon in cancer : molecular mechanisms and clinical implications Joo Mi Yi p. 1293-1305
Single-cell RNA sequencing reveals a putative lncRNA-associated ceRNA network in high-grade serous ovarian cancer Johyeon Nam, Mi-Ryung Han p. 1307-1318
Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy Eun Bin Lee, Hye Jin Yun, Su Hwan Park, Eun Hee Ko, Young Jun Jung, Rui Liu, Yun-Yong Park, Jong-Ho Lee p. 1319-1331
L1CAM enhances autophagy via inhibition of p38 phosphorylation in colorectal cancer development and progression Xiaojin Hu, Ting Wu, Yan Xie, Jin Zhou, Cong Liu, Lei Shi, Liangxi Xie, Hongtai Shi p. 1333-1342
Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma Xiaoxu Li, Liying Chen, Zhaoyang Yan, Tongxin Xu, Yan Zhao p. 1343-1353
Integrating miRNAs with QTL for identification of milk and reproduction related traits in dairy cattle Wonseok Shin, Seyoung Mun, Songmi Kim, Byung Sun Yu, Kornsorn Srikulnath, Kung Ahn, Kyudong Han p. 1355-1365
Transcriptome-based screening of regulator genes for sexual dimorphism in pupae of Callipogon relictus Kyoung-Bin Ryu, Geon Woo Lee, Sangil Kim, Chan-Jun Lee, Jun-Young Kang, Chang-Jun Kim, Sung-Jin Cho p. 1367-1377